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Abstract
Background: KIAA0101 is a proliferating cell nuclear antigen-associated factor that is overexpressed in some human
malignancies. Adrenocortical neoplasm is one of the most common human neoplasms for which the molecular causes are
poorly understood. Moreover, it is difficult to distinguish between localized benign and malignant adrenocortical tumors.
For these reasons, we studied the expression, function and possible mechanism of dysregulation of KIAA0101 in human
adrenocortical neoplasm.
Methodology/Principal Findings: KIAA0101 mRNA and protein expression levels were determined in 112 adrenocortical
tissue samples (21 normal adrenal cortex, 80 benign adrenocortical tumors, and 11 adrenocortical carcinoma (ACC). SiRNA
knockdown was used to determine the functional role of KIAA0101 on cell proliferation, cell cycle, apoptosis, soft agar
anchorage independent growth and invasion in the ACC cell line, NCI-H295R. In addition, we explored the mechanism of
KIAA0101 dysregulation by examining the mutational status. KIAA0101 mRNA (9.7 fold) and protein expression were
significantly higher in ACC (p,0.0001). KIAA0101 had sparse protein expression in only a few normal adrenal cortex
samples, which was confined to adrenocortical progenitor cells. KIAA0101 expression levels were 84% accurate for
distinguishing between ACC and normal and benign adrenocortical tumor samples. Knockdown of KIAA0101 gene
expression significantly decreased anchorage independent growth by 80% and invasion by 60% (p=0.001; p=0.006). We
found no mutations in KIAA0101 in ACC.
Conclusions/Significance: KIAA0101 is overexpressed in ACC. Our data supports that KIAA0101 is a marker of cellular
proliferation, promotes growth and invasion, and is a good diagnostic marker for distinguishing benign from malignant
adrenocortical neoplasm.
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Introduction
Adrenal neoplasms are one of the most common human
neoplasms, often detected incidentally [1]. Most adrenal neo-
plasms are benign but it is often difficult to exclude a malignant
tumor such as adrenocortical carcinoma. Adrenocortical carcino-
ma (ACC) is a rare malignancy of the adrenal cortex with a poorly
understood mechanism of development, and a dismal patient
outcome due to a lack of effective therapy [2]. The annual
incidence of ACC is approximately 1–2 cases per million [3,4,5].
Complete surgical resection is the only possible curative therapy
but over two-thirds of patients present with metastatic disease and
even those patients who have complete resection develop recurrent
disease in over 50% of cases [2,6]. Patients with metastatic disease
have a five-year survival rate of less than 10% and those with
recurrent disease have a five-year survival of only 50% [2,6].
ACC may be associated with hereditary cancer syndromes such
as Beckwith-Wiedemann syndrome (associated with germline
11p15 chromosomal alterations leading to IGF2 overexpression,
OMIM #130650), Li-Fraumeni syndrome (TP53 mutation,
OMIM #151623), multiple endocrine neoplasia type 1 (mutations
in the menin tumor suppressor gene, OMIM #131100), and
Gardner’s syndrome (APC mutation, OMIM #175100). The
genetic changes associated with hereditary cancer syndromes have
provided important information about the possible molecular
mechanisms involved in ACC. However, most cases of ACC are
sporadic, and the molecular events that lead to initiation and
progression of adrenocortical tumors remain unclear.
Genome–wide gene expression profiling provides important
insight into the molecular pathways that are dysregulated in
cancer and may be involved in tumor initiation and progression.
Since the molecular mechanism of adrenocortical carcinogenesis is
poorly understood, cDNA microarray analysis of adrenocortical
tumors has been used to reveal genes whose misexpression is
associated with ACC [7,8,9,10,11]. Among the genes that were
found to be upregulated in ACC, KIAA0101 (also known as L5;
PAF; OEATC1; NS5ATP9; OEATC-1; p15) is a novel potential
diagnostic and prognostic marker, and target for ACC therapy.
KIAA0101 encodes a proliferating cell nuclear antigen (PCNA)
-associated factor with an unknown function. KIAA0101 is
overexpressed in human malignancies such as hepatocellular and
pancreatic carcinoma [12,13,14,15,16,17,18,19,20,21,22]. How-
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to dysregulated expression of KIAA0101 is unclear.
In this study, we addressed these issues and showed that
KIAA0101 is overexpressed in ACC and a marker of cellular
proliferation. Furthermore, reducing KIAA0101 expression in
ACC resulted in growth suppression and invasion suggesting that
KIAA0101 plays an oncogenic role in ACC.
Methods
Tissue specimens
The National Cancer Institute review board approved this
research protocol after informed written consent was obtained
from all participants. Adrenal tissues were snap frozen at the time
of surgery and stored at 280uC. In this study, 112 human
adrenocortical tissue specimens were analyzed including 21
normal adrenocortical tissues, 80 benign adrenocortical tumors,
and 11 primary adrenocortical carcinomas(78 of the benign
adrenocortical tumors and 11 of the primary adrenocortical
carcinomas were previously analyzed) [11]. An independent set of
ACC metastases (n=29) and recurrences (n=2) was also used for
validation. The diagnosis of unequivocal ACC and benign
adrenocortical tumor was confirmed in all cases by histologic
examination and clinical follow up. The average follow-up time
was 26.3 months for patients with benign adrenocortical tumors
and 44.4 months for patients with ACC.
Cell culture
The NCI-H295R ACC cell line (ATCC, Rockville, MD) was
grown and maintained in DMEM supplemented with 1% ITS+
Premix (BD Biosciences, San Jose, CA), 2.5% Nu-Serum I (BD
Biosciences), and 10,000 U/mL penicillin/streptomycin in a
standard humidified incubator at 37uC in a 5% CO2 atmosphere.
Twenty-four hours after cells were seeded in 24 and 6 well plates
(4610
^4 cells in 0.5 ml and 1.6610
^5 cells in 2 ml), cells were
transfected with a nonspecific negative control siRNA and with a
KIAA0101 specific siRNA at a final concentration of 40 and
80 nM (AM4636 and AM46235, respectively, Applied Biosystems,
Foster City, CA). The TransIT siQuest reagent (Mirus Bio, LLC)
was used to deliver siRNA to the cells according to manufacturer
instructions. The knockdown efficiency was similar for 40 and
80 nM. All in vitro assays were done with both 40 and 80 nM
concentration of KIAA0101 specific siRNAs and nonspecific
negative control.
RNA and Protein Preparation
RNA was isolated using the TRIzol reagent following the
manufacturer’s instructions (Invitrogen Inc., Carlsbad, CA). RNA
quantity and quality was assessed by using NanoDrop (NanoDrop
Technologies, Inc., Thermo Fischer) and Agilent 2100 Bioanaly-
zer (Agilent Technologies, Santa Clara, CA), respectively.
RIPA buffer was used to prepare tissue lysates and whole cell
lysate was prepared with 1% SDS plus 10 mM Tris [pH 7.5]
buffer. The protein concentration was determined using the
BioRad RC DC protein assay (Hercules, CA).
Real time quantitative reverse-transcription polymerase
chain reaction (RT-PCR)
Total RNA (125 ng) was reverse transcribed using the RT script
cDNA synthesis kit (USB Corporation, Cleveland, OH). Real
time quantitative PCR was used to measure mRNA expression
levels relative to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA expression. Normalized gene expression level =
2
–( C t
of gene of interest – Ct
of GAPDH)6100%, where Ct is the PCR cycle
threshold. The PCR primers and probes for KIAA0101
(Hs00207134_m1) and GAPDH (Hs99999905_m1) were obtained
from Applied Biosystems (Assay-on-Demand kitH, Foster City, CA).
All PCR reactions were performed in a final volume of 20 ml with
1 ml of cDNA template on an ABI PRISMH7900 Sequence
Detection System (Applied Biosystems). The PCR thermal cycler
condition was 95uC for 12 minutes followed by 40 cycles of 95uCf o r
15 seconds and 60uC for 1 minute. All experiments were performed
in triplicate and repeated three times.
Western blot analysis
Proteinsamples(40 mg) wereseparatedin4% to 20%SDS-PAGE
gel and transferred onto a nitrocellulose membrane (Amersham
Pharmacia Biotech, Piscataway, NJ). Western blotting was per-
formed following standard procedures using primary mouse
monoclonal antibodies, anti-KIAA0101 (Abcam; ab56773) at
1:100 dilution and anti-b-actin (sc-81178, Santa Cruz Biotechnology
Inc, Santa Cruz, CA) at 1:2,000 dilution. Signal detection was
performed using HRP conjugated secondary antibody and an
enhanced chemiluminescence kit (Amersham Pharmacia Biotech).
Immunohistochemical (IHC) and Immuunofluoroscence
staining
Tumor tissues were formalin fixed, embedded in paraffin, and 5
micron thick sections were cut for immunostaining. Sections were
incubated with the primary anti-KIAA0101 mouse monoclonal
antibody at 1:300 dilution overnight at 4uC (Abcam; ab56773)
followed by biotinylated secondary antibody for 1 hr at room
temperature (1:150; Vector Laboratories, Burlingame, CA, USA).
Sections were developed using 3,39-diaminobenzidine DAB as the
chromogen (ABC elite kit, Vector Laboratories, Burlingame, CA,
USA) and hematoxylin as counterstain. The sections were
rehydrated and mounted with vectamount mounting medium
(Vector Laboratories, Burlingame, CA, USA). The slides were
scanned under Olympus light microscope (Nikon, Tokyo, Japan)
and pictures were taken at 20X and 40X magnifications. A
semiquantitative scoring system was used to analyze KIAA0101
expression; expression level was classified as no staining (0), ,30%
of cells staining (1), 30–50% cells (2) and .50% of cells. Two
observers, who were blinded to the tumor type, independently
scored each sample. The scores were averaged to obtain the final
KIAA0101 expression score.
Immuunofluoroscence staining was done using primary anti-
KIAA0101mouse monoclonal antibody at 1:300 dilution over-
night (Abcam; ab 56773) and rabbit anti-SF-1 (Millipore; 07-618,
Table 1. Genomic PCR Primer sequences for KIAA0101 exons.
Genomic Primer Sequences PCR product size in bp
Exon 1–2
F CCAATATAAACTGTGGCGGG 617
R AAATTCGGGCGTGAGTACC
Exon 3
F CCTTTGAGAATTTGATGTTAAAGAAG 358
R TGGCCTCAAGTGATCCTC
Exon 4
F ACAACGTAGTCTAAAGGAGAAACACTG 412
R AATTAAATGCCTGTTCAACAAAG
doi:10.1371/journal.pone.0026866.t001
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fluorophore conjugated with RedTX anti-rabbit IgG (Invitrogen,
Carlsbad, CA) and FITC anti-mouse IgG secondary antibodies
(Vector Laboratories). The slides were then rinsed and mounted
with DAPI (49,6-diamidino-2-phenylindole) mounting solution.
Images were analyzed with a Zeiss Axioskop-2 microscope at 20X
and 40X magnifications.
DNA Purification
Genomic DNA was isolated from 1 mg of tumor and normal
samples using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden,
Germany), eluted in a total volume of 200 mL and stored at
220uC. DNA concentrations were measured by UV absorbance
using NanoDrop (NanoDrop Technologies, Inc., Thermo Fischer).
Sequencing KIAA0101 coding region
The KIAA0101 exons 1, 2, 3 and 4 were sequenced. PCR
primers were designed for coding region using UCSC genome
browser, Primer 3 integrated software. The primer sequences are
listed in Table 1. Primers were made by IDT, Inc. (Coralville,
IA). Exons 1, 2, 3 and 4 were amplified as three separate reactions
in 50 ml using PCR master mix (Fermentas Inc. USA). The
standard PCR conditions were initial denaturation at 95uC for
5 min followed by 30 cycles of denaturation at 95uC for 5 min,
annealing at 50uC for 1 min, extension at 72uC for 1 min and final
extension at 72uC for 10 min. PCR products were visualized on
2% agarose gel. The products were purified using standard Exo-
nuclease I and FastAP (Fermentas Inc.). Purified PCR products
were sequenced using ABI sequencer 3730xl with big dye method
(DNA Sequencing kit, big dye terminator cycle sequencing;
Applied Biosystems). Mutations were analyzed by the Mutation
Surveyor V 3.3 Programme (Soft Genetics; www.softgenetics.
com). All of the sequencing data has been deposited in GenBank.
Cell proliferation
Cells were seeded in a 96-well plate at a concentration of
5610
^3 cells per 100 mL culture medium in six replicates. At each
timepoint, the media was aspirated from the well and the cells
were immediately frozen at 280uC for 24 hours. The plates were
thawed at room temperature, and prepared for cell number
quantification using the CyQUANT
TM assay kit (Invitrogen,
Carlsbad, CA). The CyQuant assay was performed according to
the manufacturer’s instructions, and analyzed on a fluorometric
microplate reader (Molecular Devices, Sunnyvale, CA) at
480 nm/520 nm.
Flow cytometry and apoptosis analyses
KIAA0101 and negative control siRNA treated cells were
harvested, ethanol-fixed overnight at 4uC, and resuspended in 1x
PBS to a concentration of 1610
^6 cells/mL. Cells were treated
with DNase-free RNase (100 mg/ml) for 20 min at 37uC. The cells
were stained with propidium iodide at concentration of 50 mg/ml
and samples were stored at 4uC. Flow cytometric analysis was
performed on a Becton Dickinson FACScan (BD Biosciences,
Franklin Lakes, NJ). Data files were generated for 20,000 events
(cells) using the CellQuest software. The fraction of the total cell
population present in each of the G1, S and G2/M cell cycle
phases was obtained from ModFit LT software (Verity Software
House, Inc.). Apoptosis analysis was performed using Annexin V
staining (ApoAlertH Annexin V Apoptosis Kit) according to the
manufacturer’s instruction (Clontech, Mountain View, CA).
Soft agar anchorage independent growth assay
Two-layered soft agar assays were performed in six-well plates.
The bottom layer of agar (2 ml/well) contained 0.5% agar (Difco
Noble Agar, Becton, Dickinson and Company, Sparks, MD) in
maintenance medium. Five days after siRNA transfection, cells
were trypsinized, counted, and 50,000 cells were mixed with
1.3 ml of top agar solution supplemented with 10% Nu-serum
(0.3% agar in culture media). Solidified agar was overlayed with
1 ml of culture media containing 10% Nu-serum. The plates were
cultured at 37uCi n5 %C O 2, and the media was changed twice a
week. After 16 days of culture, cell colonies were stained with 0.2%
crystal violet solution and examined by microscopy. Colonies were
counted in 5 different fields per well and confirmed by TotalLab
Quant v11 software (http://www.totallab.com/).
Cell invasion assay
The extent of cell invasion was assessed using the BD
BioCoat
TM Matrigel
TM Invasion Chamber (BD Biosciences,
Bedford, MA), according to the manufacturer’s protocol. A total
of 1610
^5 cells were seeded onto the inserts (8-mM pore sized
polycarbonate membrane) coated with a thin layer of Matrigel
Basement Membrane Matrix (BD Biosciences). The inserts were
placed into a 24-well plate with 10% serum-containing culture
medium or media without serum. The plates were incubated for
48 hrs at 37uC. Cells that invaded the Matrigel matrix to the lower
surface of the membrane were fixed and stained with Diff Quik
Stain (Dade Behring, Newark, DE, USA) and counted under a
light microscope. Four fields in four separate quadrants of each
membrane were counted and averaged.
Figure 1. Expression of KIAA0101 mRNA in ACC. A) KIAA0101 mRNA expression in normal adrenal cortex (n = 21), benign adrenocortical
tumors (N = 80), ACC (N = 10), metastatic and recurrent ACC (n=30) and the NCI-H295R cell line. KIAA0101 mRNA expression level was determined
by quantitative RT-PCR and normalized to GAPDH mRNA expression. Columns represent mean 6 standard deviation of replicate determinations.
Statistical significant difference is indicated by an asterisk (*) (p,0.05, Kruskal Wallis test). Primary ACC vs. normal (p,0.0001), primary ACC vs. benign
adrenocortical tumors (p,0.0001) and primary ACC vs. metastases (p,0.0001). B) ROC curve analysis for KIAA0101 mRNA expression. The receiver
operating characteristic curve (ROC) is depicted on graph using RT PCR expression data of KIAA0101 normalized to GAPDH in normal adrenal cortex
(n = 21), benign adrenocortical tumors (n = 80), ACC (n = 10) . The area under the curve (AUC) was 0.78. A perfect diagnostic marker without any
false-negatives or false-positives would have an AUC of 1. C) KIAA0101 protein expression in ACC. KIAA0101 protein expression levels in normal
adrenal cortex (n=5), benign (n=13), and malignant adrenocortical tumors (n=3) as shown in representative Western blot with KIAA0101 specific
and b-Actin control antibodies. b-Actin signal was used as a control for protein loading. C = ACC, B = benign adrenocortical tumor, and N = normal
adrenal cortex. D) Scatter plot of KIAA0101 mRNA and protein expression level in normal, benign and malignant adrenocortical tissue samples. Y-axis
shows normalized mRNA expression by quantitative RT-PCR and X-axis shows protein expression level in the same sample based on band
densitometry measurement normalized to b actin expression level. Spearmen correlation coefficient (r) =0.61, p,0.001. E) Immunohistochemistry
for KIAA0101 protein expression in normal adrenocortical tissue, benign tumors and ACC. Representative images are shown for each category at 20X
magnification. Arrow indicates the positive nuclear staining for KIAA0101. In normal tissue samples, only the subcupsular region was positive.
F) KIAA0101 cellular localization was analyzed by immunoflouroscence. Nuclei were stained by DAPI (blue), red color indicates KIAA0101 expression.
Representative images from malignant ACC and normal samples are shown at 20X magnification.
doi:10.1371/journal.pone.0026866.g001
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The continuous data was represented as mean 6 standard
deviation (S.D.). Two-tailed ANOVA multi-comparison t-test was
used to assess the difference between mean expression among
normal, benign and malignant samples. Pearson correlation test
were used for continuous data. A p-value ,0.05 was considered as
significant. The analysis was done by Stat View 5.0 (Cary, NC)
and SPSS v 16.0 (Chicago, IL) statistical softwares.
Figure 2. KIAA0101 and Steroidogenic factor 1(SF-1) protein expression in progenitor cells of normal adrenal cortex tissue by
immunohistochemistry and immunofluoroscence. A) Immunohistochemistry staining of normal adrenal cortex for SF-1 and KIAA0101.
In the first panel, the zones of the adrenal cortex are indicated at 10X, 1: Zona glomerulosa containing progenitor cells, 2: Zona fasciculata, 3:
Zona Reticularis. Second and third panel indicate the SF-1 (20X with 40X inset) and KIAA0101 positive immunostaining in the Zona Glomerulosa
at 20X magnification. Red arrows indicate the positive areas for SF-1 and KIAA0101 staining. B) Immunofluoroscence for SF-1 and KIAA0101 in
the normal adrenal cortex. Nuclei were stained by DAPI (blue), red color indicates KIAA0101 expression and green color indicates SF-1
expression. Merged Images (yellow color) at 40X show colocalization of the two proteins, SF-1 and KIAA0101 in progenitor cells of normal
adrenal cortex.
doi:10.1371/journal.pone.0026866.g002
Table 2. Summary of sequencing changes in KIAA0101.
Variations Position Region Distribution
Normal (n=8)* Benign (n=75)* Malignant (n=10)
88T.C EXON 1–2 59 UTR 1/8 (12.5%) 5/75 (6.6%) ND
410T.C EXON 1–2 Intronic 1/8 (12.5%) ND** ND
15360T.C EXON 4 Intronic ND** 1/75 (1.3%) ND
*Percentage of mutation is for the samples which were analyzed by category and available for sequencing.
**ND (not detected).
doi:10.1371/journal.pone.0026866.t002
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KIAA0101 mRNA and protein are highly expressed in
adrenocortical neoplasm
The expression of KIAA0101 mRNA was significantly higher in
ACC as compared to normal adrenocortical tissue and benign
adrenocortical tumors (12-fold higher than normal and 9-fold
higher than in benign tumors, p,0.0001) (Figure 1A). In
addition, KIAA0101 mRNA expression level was lower in
metastatic and recurrent tumors as compared to primary ACC
(p,0.001)
Given the significant expression difference in mRNA between
benign and malignant tumors, we were interested in assessing if
KIAA0101 was an accurate diagnostic predictor of tumor type.
KIAA0101 expression was 84% accurate for distinguishing
between ACC and normal and benign adrenocortical tumor
samples (number of true positive and negative results divided by
the total sample number using a cutoff level of 1.5). The area
Figure 3. KIAA0101 mRNA and protein expressions were decreased with siRNA knockdown in the NCI-H295R adrenocortical
carcinoma cell line. A) H295R cells were transfected with KIAA0101 siRNA and negative control and analyzed for KIAA0101 mRNA expression after
48 hours of treatment. Columns represent KIAA0101 mRNA expression percentage relative to negative control 6 standard deviation of four
experiments. B) Representative Western blot demonstrating protein expression of KIAA0101 after 6 days of siRNA and negative control. C) Relative
intensity of western blot using Image J Software. Columns indicate ratio of KIAA0101 and GAPDH intensity measurements. NC40=Negative control at
40 nM; SI40 = siRNA at 40 nM; NC80 = Negative control at 80 nM; SI80 = siRNA at 80 nM.
doi:10.1371/journal.pone.0026866.g003
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0.78 for KIAA0101 mRNA expression (Figure 1B), 0.79 for
tumor size, and 0.85 for combination of KIAA0101 expression
and tumor size.
In addition to high mRNA expression, KIAA0101 protein
expression was also elevated in ACC as compared to normal
adrenal cortex and benign adrenocortical tumor samples. On
Western blot, we found higher expression in ACC (n=3) than
benign adrenocortical tumors (n=13), and in normal adrenal
cortex samples (n=5) (Figure 1C). There was good correlation
between KIAA0101 mRNA and protein expression levels
(Figure 1D, r=0.61, p,0.001). To further assess KIAA0101
expression, we performed semiquantitative analysis of a tissue
array containing small sections of benign and malignant tumors by
immunohistochemistry for KIAA0101 protein. This analysis found
no significant difference in KIAA0101 protein expression between
benign and malignant tumors (p=0.31). This is not surprising as
immunohistochemistry is a semiquantitative method and may not
detect smaller differences in protein expression. However, when
KIAA0101 protein expression was evaluated in individual benign
and malignant samples on the array, significant overexpression
was observed as compared to normal samples (Figure 1E).
KIAA0101 protein was present in the cytoplasm and nucleus,
which was also confirmed by immunofluorescence (Figure 1F).
We observed only sparse KIAA0101 staining in a few normal
adrenal cortex samples, which was confined to the subcapsular
cortex region (Figure 2A). To determine if this focal area positive
for KIAA0101 represented adrenal progenitor cells, we co-stained
the same normal adrenal cortex samples with steroidogenic factor
1 (SF-1) antibody, a marker of adrenal progenitor cells [23].
Interestingly, normal adrenal cortex samples showed co-staining of
KIAA0101 and SF-1 together in the subcapsular or progenitor
region of the adrenal cortex (Figure 2B).
Mechanism of KIAA0101 overexpression in ACC
To determine whether the KIAA0101 overexpression was a
consequence of gene sequence variations, we performed mutation
analysis in the KIAA0101. We found one de novo G.A transition
mutation at position 186 which falls in non-coding region of
KIAA0101 in a benign sample. We also observed one polymor-
phism in the 59 UTR in exon 1–2 (88T.C). About 6.6% of benign
were heterozygous and 12.5% in the normal but none in
malignant samples (Table 2). Given these results it is unlikely
that the KIAA0101 overexpression is a result of mutation.
The functional effect of knockdown of KIAA0101 gene in
an ACC cell line
Given the significant overexpression of KIAA0101 in ACC
(Figure 1) and the observation that KIAA0101 expression is
restricted to proliferating adrenal progentitor cells (Figure 2B),
we hypothesized that KIAA0101 plays a role in adrenocortical cell
growth. To address this, we used siRNA to knockdown KIAA0101
expression in the ACC cell line, NCI-H295R. Transient trans-
fection of KIAA0101 specific siRNA resulted in a 10-fold
knockdown within 24 hours and this effect was sustained for up
to 6 days at the mRNA and 80% reduced at the protein levels as
compared to a non targeting siRNA (negative control siRNA)
(Figure 3). KIAA0101 knockdown resulted in modest increase in
cellular proliferation with an increase in cell number of up to 25%
(p=0.005) (Figure 4A). Also, the cell line doubling time and
growth rate were different for siRNA knockdown as compared to
the negative control (average doubling time of 4.7 and growth rate
of 0.14 as compared to average doubling time of 3.5 and growth
rate of 0.19 from day 1 to 5, respectively). Cell cycle analysis
revealed a modest increase in the number of cells in G1 phase
(p=0.013) (Figure 4B). Considering these contradictory results,
we also evaluated mRNA expression of G1 cell cycle regulatory
proteins at G1 phase after KIAA0101 knockdown. KIAA0101
knockdown did not significantly alter the mRNA expression of p21
and Cyclin D1, cell cycle regulatory proteins, in an ACC cell line.
In addition, KIAA0101 gene knockdown had no significant effect
on the number of cells in apoptosis (data not shown).
Given the paradoxical effects, a modest increase in cellular
proliferation and G1 arrest, we used additional functional assays to
better understand the phenotypic changes associated with
KIAA0101 knockdown. Specifically tumorogenicity and metastat-
ic potential were evaluated. KIAA0101 knockdown in NCI-
H295R cells reduced the number of colonies that were able to
grow in soft agar by almost 80% (p=0.001) at 16 days of culture
(Figures 5A and 5B) with a 60% reduction in cell invasion in the
NCI-H295R cell line (p=0.006) (Figures 5C and 5D).
Discussion
In this study, we examined KIAA0101 expression and function
in ACC. Our results indicate that KIAA0101 is overexpressed in
ACC, is a good diagnostic marker for ACC, and is a marker of
cellular proliferation. Suppressing KIAA0101 expression in
adrenocortical carcinoma cells resulted in suppression of growth
and invasion, suggesting that it plays a growth promoting role in
ACC.
Previous studies have demonstrated altered expression of
KIAA0101 in human malignancies and absent or low expression
in normal tissue [12,13,14,15,16,17,18,19,20,21,22]. However,
conflicting results have been obtained for KIAA0101 expression
in hepatocellular carcinoma (HCC). In one study, KIAA0101
expression was found to be downregulated in HCC [13].
Conversely, in a separate study, in a large cohort of patients with
HCC, KIAA0101 was upregulated[18]. Our study also demon-
strated the KIAA0101 overexpression in primary ACC but,
interestingly, KIAA0101 mRNA expression was lower in tumors
from a cohort of patients with metastatic and recurrent ACCs who
responded to systemic chemotherapy and underwent resection.
These results suggest that KIAA0101 expression may vary as a
result of treatment and could possibly be used as a biomarker for
treatment response in ACC and other cancers.
Although we found that KIAA0101 protein expression was
higher in malignant and benign tumors as compared to normal
samples, we did detect KIAA0101 expression in a subset of normal
samples. Its expression was confined to the subcapular region of
the adrenal cortex and overlapped the SF-1 positive staining cells.
Figure 4. Cell proliferation increased with KIAA0101 siRNA knockdown in the NCI-H295R cell line. A) The number of cells for the
KIAA0101 siRNA treated and negative control treated groups are shown at indicated time points (significant values are indicated by asterisk (*) (p =
0.005; relative to negative control). Error bars represent 6 standard error of mean and is representative of four experiments. NC80=Negative control
at 80 nM; SI80 =siRNA at 80 nM. B) KIAA0101 gene knockdown and cell cycle analysis is indicated at different time points. Representative image of
cell cycle profile from siRNA and negative control treatment groups. C) Each column indicates the distribution of G0/G1 population of cells in each
group at various time points. Error bars represent 6 standard error of mean and is representative of four experiments.*Day 3 and 5, p,0.05; relative
to negative control.
doi:10.1371/journal.pone.0026866.g004
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cultured for 15 days in the presence of indicated concentrations of siRNA and negative control. Representative images are shown at 12X and 40X
magnifications. B) The distribution and number of colonies in group treated with KIAA0101 siRNA and negative control group at 80 nM (p=0.001;
relative to negative control; NC80= Negative control at 80 nM; SI80 =siRNA at 80 nM). Error bars represent 6 standard error of mean and is
representative of four experiments. C) Invading cells were stained with 0.2% crystal violet and visualized by microscopy. Representative images at
20X following invasion assay. D) The distribution of number of cells in KIAA0101 siRNA and negative control group. Columns represent the mean 6
standard deviation (SD) of three independent experiments performed in triplicate. *p,0.05 KIAA0101 siRNA vs. negative control. H295R cells were
transfected with negative control or KIAA0101 siRNA at 80 nM for 120 h, followed by an invasion assay for 48 h.
doi:10.1371/journal.pone.0026866.g005
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progenitor cells [24]. Progenitor cells possess high proliferative
capacity. KIAA0101 and SF-1 co-expression in the progenitor
region of normal adrenal cortex suggests that KIAA0101 may be a
marker of proliferation in adrenocortical cells. Consistent with this,
a study by Simpson et al., has demonstrated the localization of
KIAA0101 in basal cell layer of the skin and the proliferative zone
in the crypts of the colon[15].
Little is known about the function of the KIAA0101 gene in
tumor cell biology. Previously, studies have suggested that
KIAA0101 is involved in the regulation of DNA replication, cell
cycle, apoptosis and cellular proliferation [13,14,15,18,25,26].
Given that KIAA0101, under basal culture conditions, was highly
expressed in the NCI-H295R cell line, we used a gene silencing
strategy to effectively knockdown its expression. Using this
strategy, we observed a modest increase in cellular proliferation,
suggesting that KIAA0101 may have a growth suppressive
function in ACC. In addition to the growth regulatory function
of the KIAA0101 gene, we observed that KIAA0101 knockdown
slightly increased the number of cells in G1 phase with a
concomitant decrease in the number of cells in S phase. This result
suggests that KIAA0101 may function as a cell cycle checkpoint
protein for G1/S phase cell cycle transition. Indeed, KIAA0101
encodes a 15-kDa protein, which contains a conserved prolifer-
ating cell nuclear antigen (PCNA) binding motif, and was initially
discovered in a study screening for binding partners for the PCNA
in yeast [20]. KIAA0101 shares the PCNA binding motif with
many important cell cycle regulatory PCNA binding proteins such
as p21, p57 and p33ING1b [27]. KIAA0101 also competes with
p21 for binding to PCNA and regulate cell cycle progression [20].
In our study, it is possible that after knockdown of KIAA0101, p21
may bind to PCNA and leads to G1/S arrest. However, given the
modest effect on cell cycle progression, we did not find significant
influence on p21 and CyclinD1 levels of G1 cell cycle phase
proteins. On the other hand, knockdown of KIAA0101 greatly
reduced anchorage independent growth and invasion. It strongly
indicates that KIAA0101 expression in adrenocortical tumor
cells might contribute to tumor progression. These seemingly
contradictory effects are consistent with previous observations
[13,14,18]. A study by Hosokowa et al. demonstrated the potential
oncogenic role of KIAA0101 in pancreatic cancer [14]. They
overexpressed KIAA0101 exogenously in NIH3T3 fibroblast cells
which revealed in vivo cancer cell growth, confirming its growth-
promoting and oncogenic nature. Similarly, in HCC, it has been
shown that KIAA0101 overexpression was associated with higher
vascular invasion and contributes to poor prognosis [18].
However, in another study of HCC, KIAA0101 was downregu-
lated and found to be a growth-inhibitory gene [13]. Specifically,
depending on the tumor type and cell line studied, KIAA0101 has
been found to have both growth inhibitory and stimulatory effects
[13,14,15,16,18,20]. Such paradoxical effects on growth and cell
cycle progression (growth promoting or inhibiting effects) of key
cell cycle regulating genes, such as p21 and p27, have also been
observed depending on cell type and external cell stimuli or stress
factors [28].
While most genes upregulated in malignancy have a growth
promoting function, one of the most common tumor suppressor
genes in human malignancy, p53, is overexpressed and has a
tumor suppressor function because of inactivating dominant
negative mutations. In our study, KIAA0101 was also overex-
pressed, therefore, we hypothesized that sequence alterations may
reveal the reason for dysregulation. However, we did not detect
the presence of such mutations in coding region of KIAA0101
consistent with one other study [20]. However, previous studies
have revealed that the genomic region of KIAA0101, chromo-
somal locus 15q is frequently gained in ACC [29,30]. Additional
studies in a large set of ACCs will be necessary to determine the
molecular mechanism for KIAA0101 overexpression.
In summary, the results of our study provide the first evidence
that KIAA0101 is a marker of cell proliferation and is
overexpressed in ACC, therefore it suggests that its expression
could be used as a molecular marker for the diagnosis of ACC. In
addition, our functional studies suggests, it has modest effect on the
cell proliferation and cell cycle progression. However, the majority
of the results support that it is a potential tumor-promoting gene
and contributes to metastatic potential in vitro.
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